EULAV Asset Management Has $14.10 Million Holdings in Insmed, Inc. $INSM

EULAV Asset Management lessened its stake in Insmed, Inc. (NASDAQ:INSM) by 10.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,000 shares of the biopharmaceutical company’s stock after selling 9,000 shares during the quarter. EULAV Asset Management’s holdings in Insmed were worth $14,097,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Artisan Partners Limited Partnership lifted its holdings in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Atika Capital Management LLC purchased a new stake in Insmed during the 3rd quarter worth about $13,681,000. iA Global Asset Management Inc. lifted its holdings in Insmed by 15,973.5% during the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock worth $4,644,000 after purchasing an additional 26,516 shares in the last quarter. Nordea Investment Management AB purchased a new stake in Insmed during the 4th quarter worth about $3,492,000. Finally, Essex Investment Management Co. LLC lifted its holdings in Insmed by 31.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 87,077 shares of the biopharmaceutical company’s stock worth $12,540,000 after purchasing an additional 20,732 shares in the last quarter.

Insmed Stock Performance

NASDAQ:INSM opened at $94.22 on Friday. The business’s 50-day moving average price is $130.45 and its two-hundred day moving average price is $154.95. Insmed, Inc. has a twelve month low of $70.57 and a twelve month high of $212.75. The stock has a market cap of $20.42 billion, a P/E ratio of -16.39 and a beta of 0.79. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company’s revenue was up 229.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.42) EPS. As a group, equities analysts predict that Insmed, Inc. will post -2.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on INSM shares. Raymond James Financial assumed coverage on Insmed in a report on Friday, April 10th. They set an “outperform” rating and a $200.00 price objective on the stock. Jefferies Financial Group assumed coverage on Insmed in a report on Monday, March 16th. They issued a “buy” rating and a $228.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Mizuho raised their price target on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Finally, Leerink Partners raised their price target on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $210.50.

Insider Transactions at Insmed

In other news, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the transaction, the insider directly owned 51,871 shares in the company, valued at approximately $7,831,483.58. This represents a 27.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sara Bonstein sold 2,404 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This trade represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 160,482 shares of company stock valued at $24,438,193 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.